PROCEPT Biorobotics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated July 23, 2025, reports on significant corporate governance changes and provides a reference to estimated revenue for the quarter ended June 30, 2025. The filing details the appointment of a new Chief Executive Officer and the departure of the incumbent CEO.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing estimated revenue for the quarter ended June 30, 2025, but does not disclose specific revenue, profit, cash flow, margin, debt, or liquidity figures within the text of this report. The document focuses on executive compensation arrangements rather than operational financial performance.
Material Changes and Executive Compensation
- Leadership Transition: Larry L. Wood was appointed President and CEO, effective September 2, 2025. Reza Zadno will step down from his executive roles on September 1, 2025, transitioning to a consulting role.
- New CEO Compensation (Mr. Wood):
- Base Salary: $925,000 annually.
- Target Annual Bonus: 100% of base salary.
- Sign-on Bonus: $1,700,000 (cash).
- Equity Awards: Approximately $7.5 million in "Buy-Out" RSUs, $7.5 million in stock options, and $3.0 million in performance stock units.
- Severance: 1.5x base salary for termination without cause; 3x base salary plus target bonus for termination near a change in control.
- Outgoing CEO Compensation (Dr. Zadno):
- Severance: 12 months of base salary paid as a lump sum.
- Benefits: COBRA coverage for up to 12 months and a pro-rated 2025 target bonus.
- Equity: Accelerated vesting of 2025 equity awards consistent with qualifying retirement terms.
Outlook, Risks, and Management Commentary
The Board conducted an extensive succession search to appoint Mr. Wood, citing his over 40 years of experience in the medical technology industry, including leadership roles at Edwards Lifesciences Corporation. The filing explicitly states that Dr. Zadno's departure is not the result of any disagreement regarding operations, policies, or practices. No specific financial guidance or risk factors were disclosed in this filing beyond the standard executive transition risks.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific estimated revenue figures for the quarter ended June 30, 2025, which are not detailed in this 8-K text.
- Verify the total dilution impact of the $18 million in equity awards granted to the new CEO.
- Confirm the exact vesting schedule and performance metrics for the $3 million performance stock units to be granted in Q1 2026.
- Monitor the transition period to ensure operational continuity as Dr. Zadno moves to a consulting role.